anti-NaPi2b antibody-drug conjugate XMT-1592

{
  "id": "MLC-T-ONC-010912",
  "term": "anti-NaPi2b antibody-drug conjugate XMT-1592",
  "field": "Oncology and biomedicine",
  "definition": "An antibody-drug conjugate (ADC) composed of XMT-1535, a humanized monoclonal antibody against human sodium-dependent phosphate transport protein 2B (SLC34A2; NaPi2b), that is site-specifically bioconjugated to the cytotoxic aurastatin derivative auristatin F-HPA (AF-HPA; auristatin F-hydroxypropylamide), with potential antineoplastic activity. Upon administration of anti-NaPi2b ADC XMT-1592, the antibody moiety targets and binds to NaPi2b expressed on tumor cells. Following internalization of XMT-1592 and release of AF-HPA, the AF-HPA binds to tubulin and inhibits microtubule polymerization, which results in G2/M phase arrest and apoptosis of NaPi2b-expressing tumor cells. NaPi2b, a tumor-associated antigen (TAA), is overexpressed on a variety of cancer cells and plays a key role in the transport of inorganic phosphate (Pi) and the maintenance of phosphate homeostasis.",
  "synonyms": [
    "NaPi2b-targeted antibody-drug conjugate XMT-1592",
    "anti-NaPi2b ADC XMT-1592",
    "anti-NaPi2b/auristatin F-HPA ADC XMT-1592"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-napi2b-antibody-drug-conjugate-xmt-1592/"
}